Based on the aggregated intelligence of 180,000-plus investors participating in Motley Fool CAPS, the Fool's free investing community, biopharmaceutical company Sunesis Pharmaceuticals (SNSS) has received the dreaded one-star ranking.
With that in mind, let's take a closer look at Sunesis and see what CAPS investors are saying about the stock right now.
Sunesis facts
|
Headquarters (founded) |
South San Francisco, Calif. (1998) |
|
Market Cap |
$319.3 million |
|
Industry |
Biotechnology |
|
Trailing-12-Month Revenue |
$1.8 million |
|
Management |
CEO Daniel Swisher Jr. (since 2004) |
|
Return on Equity (average, past 3 years) |
(53.5%) |
|
Cash/Debt |
$76.6 million / $24.0 million |
|
Competitors |
AstraZeneca |
Sources: S&P Capital IQ and Motley Fool CAPS.
On CAPS, 41% of the 32 All-Star members who have rated Sunesis believe the stock will underperform the S&P 500 going forward.
Earlier this week, one of those Fools, All-Star zzlangerhans, succinctly summed up the bear case for our community:
The Sunesis seems to be rising again but it looks to me like a rising tide phenomenon. As I've said before, the requirement to increase enrollment after the interim analysis last September was the second worst possible outcome. VALOR is unlikely to return a positive result and there is absolutely no reason for the share price to be rising more than a year ahead of topline data. It seems the lessons of Celsion haven't been learned.
Want to see how well (or not so well) the stocks in this series are performing? Follow the TrackPoisedTo CAPS account.
